A Clinical Study of Endoscopic Submucosal Hormone Injection Combined with Dilation for Esophageal Stricture after Endoscopic Submucosal Dissection (ESD) for Early Esophageal Cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600124399

Enrollment

Unknown

Registered

2026-05-12

Start date

2026-01-10

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early esophageal cancer

Interventions

Oral steroid combined with endoscopic submucosal steroid injection group:Oral steroid combined with endoscopic submucosal steroid injection

Oral steroid:Oral steroid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with early esophageal cancer who develop a mucosal defect involving >=3/4 or the entire circumference after endoscopic submucosal dissection (ESD).

Exclusion criteria

Exclusion criteria: 1:Failure of vital organs, including the heart, liver, and kidneys; 2:Patients who have used systemic glucocorticoids (e.g., prednisone, methylprednisolone, etc.) continuously for more than 1 week within 4 weeks before ESD; 3:Poorly controlled diabetes mellitus: glycated hemoglobin (HbA1c) >= 7.0%;; 4:Concomitant other malignancy; 5:Patients with pre-existing esophageal stricture before ESD.

Design outcomes

Primary

Measure	Time frame
Endoscopic findings of esophageal stricture (inability to pass a standard gastroscope with a diameter of 9.2 mm);	—

Secondary

Measure	Time frame
Number of expansions;Time from first expansion to ESD operation;Incidence of adverse events;	—

Countries

China

Contacts

Public ContactJiang Zhonghua

Yancheng N0.1 People’s Hospital

jiangzhonghua1982@163.com+86 158 6204 3475

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026